RankAlpha logo
Back to Rankings

PODD

InsuletD
Nasdaq / Health Care Equipment & Services
Last Price
At close
2026-07-18
View Chart
Current thesis
Primary-source earnings evidence was strong: revenue growth exceeded guidance, operating margin expanded, free cash flow rose to $89.5 million, and FY2026 revenue guidance was raised. The operating story is still centered on Omnipod adoption, especially international, with additional pipeline optionality from type 2 AID.
Posture
Defensive
Lead driver
Value
What changed
Value remains the lead driver in the composite, 7D delta -0.2.
What can break
Direct diabetes-technology competition from Tandem and Medtronic can pressure new-user acquisition, retention, pricing, and the perceived differentiation of tubeless AID over time.
Momentum
15
Value
56
Sentiment
56
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $172.00 · Bull $205.00 · Bear $130.00
Data freshness
Prices
As of 2026-07-18
Fundamentals
As of 2026-07-17 • Vendor: Data Vendor v1
Scores
As of 2026-07-18 • Model: HYBRID_IC_RP
AI Memo
As of 2026-05-09 • Model: RankAlpha Sentiment Codex
Investment thesis
As of 2026-07-18
Supporting evidence
What
Grade D · Defensive
Confidence Medium · Net Neutral
Target $234.95
Why
Momentum15 · Δ7d +9.8
Value56 · Δ7d -0.2
Sentiment56 · Δ7d -4.9
So what
Weak posture (Net Neutral). Prioritize risk control and patience.
Lead driver: Value · See fundamentals
Momentum
15
26% active weight
Current posture
7d trendImproving
Δ7d
+9.8
Δ21d
+17.0
Value
56
39% active weight
Current posture
7d trendFlat
Δ7d
-0.2
Δ21d
+0.0
Sentiment
56
34% active weight
Current posture
7d trendSoftening
Δ7d
-4.9
Δ21d
-4.8
Why this grade

Composite grade D. Momentum 14.8 / Value 56.3 / Sentiment 55.6

Fundamentals (TTM)
As of 2026-07-17
Market Cap
$11.36B
Beta
1.41
Shares Out
69.26M
P/E (TTM)
82.3
P/S (TTM)
7.91
P/FCF (TTM)
48.92
Rev YoY
+33.9%
EPS YoY
+158.5%
Gross Margin
+71.6%
Op Margin
+12.4%
Net Debt
$285.8M
Current Ratio
2.45
As of 2026-07-18 • Updated nightlySource: Internal modelMethodology